HDAC9 and Stroke: In keeping, prospective examination demonstrated reduced stroke risk in epileptic patients that were prescribed sodium valproate (SVA), a short chain fatty acid class I HDAC inhibitor, as compared to non-SVA prescribed patients or antiepileptic drug (AED) prescribed patients [118].